CytoDyn Initiates Pre-Clinical Study of Leronlimab (PRO 140) to Prevent NASH with The Cleveland Clinic’s Dr. Daniel J. Lindner, M.D., Ph.D.


You May Also Like

Atara Biotherapeutics to Present at Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 24, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) ...

Rexahn Effects 1-for-10 Reverse Stock Split

ROCKVILLE, Md., May 05, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) (“Rexahn” ...